Yes Jalaluddin, some are dummy and some are waiting out of sight, is not just a Mexican standoff, is an ambush as well.
Elke, whatever makes more financial sense: some drugs may need a partnership for both research and to finance their development through the FDA's approval, others may not. If there's an offer for cash consideration with a 20/30% premium on the MC, the directors will give their recommendations to the shareholders for approval.
I wouldn't be surprised if next year, especially following the results of Phase II for BTX1503, and with more data coming out of other products trials, BOT 'll either have a series of agreements in place or will be the object of cash bids from big pharmas.
Yes Jalaluddin, some are dummy and some are waiting out of...
Add to My Watchlist
What is My Watchlist?
